Substrate AI finalizes the acquisition of the adhesive label producer Ibi in full IPO

MADRID, 15 May.

Substrate AI finalizes the acquisition of the adhesive label producer Ibi in full IPO

MADRID, 15 May. (EUROPA PRESS) -

Substrate AI finalizes the acquisition of the adhesive label producer Ibi, an operation that it expects to close at the end of May and whose negotiations are taking place in parallel to its exit to BME Growth, scheduled for Tuesday, May 17.

Adhesivas Ibi will contribute to the group an annual turnover of 4.7 million euros with a gross operating profit (Ebitda) of 953,000 euros and 42 employees on the workforce, according to the information provided to investors by Substrate AI consulted by Europa Press.

The company, which also carries out design work, will also contribute 925,000 euros of financial debt and will be the group's second acquisition this year after Fourth Medical Dimension.

In a presentation to investors, the company explained that part of its strategy is to grow based on the purchase of companies with solid businesses in different verticals.

In these companies, the company will apply its artificial intelligence solutions to optimize their operation and profitability while reinvesting the cash flows it generates.

The company, previously called Zonavalue, will begin trading on BME Growth on May 17 with a valuation of 95 million euros and through a 'technical listing' of 22 million shares at 4.3 euros due to the atomized nature of its shareholding, which does not necessitate a sale of shares.

The company expects to invoice, thanks to its acquisition strategy, more than eight million euros in 2022, a figure that it expects to rise to almost 18 million euros in 2023.

The company offers services in the verticals of Fintech, Human Resources, Industry, Energy, Agritech and Health and next year it will start its activity in Mining and Contact Center.

The prospectus details that, in the short and medium term, the profits generated by the company will be reinvested to develop new products with which no dividends are expected and there is no policy to distribute them.


3

NEXT NEWS